Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
NCT01185548 · Eli Lilly and Company · PHASE1 · terminated · last registry update 2018-10-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Terminated based on safety results from another trial” | – | Registry record, Eli Lilly and Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KCNJ11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-09-12Phase 3 first posted: Soleno Therapeutics, Inc., DCCR (NCT04086810)
- 2019-09-06Results posted on the registry: Kissei Pharmaceutical Co., Ltd., KAD-1229 + Placebo (NCT02154347)
- 2019-07-26Results posted on the registry: Hospices Civils de Lyon, Minoxidil + Placebo (NCT00876200)
- 2019-07-16Results posted on the registry: Merck KGaA, Darmstadt, Germany, Metformin/Gliclazide Fixed Combination + Metformin (NCT03467945)
- 2019-07-08Results posted on the registry: Merck KGaA, Darmstadt, Germany, Metformin/Gliclazide Fixed Combination (NCT03467971)
- 2018-11-26Phase 3 first posted: Farid Masoud, Topical Herbal Solution + Topical Minoxidil 5% (NCT03753113)
- 2018-10-22Phase 3 first posted: Soleno Therapeutics, Inc., DCCR + DCCR (NCT03714373)
- 2018-09-13Results posted on the registry: University of Washington, Linagliptin + Glipizide (NCT02608177)
- 2018-05-03Also stopped (terminated): NHS Tayside, gliclazide (NCT00738088)
- 2018-02-22Phase 3 first posted: Soleno Therapeutics, Inc., DCCR + Placebo for DCCR (NCT03440814)
- 2017-10-26Results posted on the registry: University of Dundee, Gliclazide MR + Sitagliptin (NCT00780715)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision